Form 8-K - Current report:
SEC Accession No. 0001193125-23-293433
Filing Date
2023-12-12
Accepted
2023-12-12 16:36:54
Documents
15
Period of Report
2023-12-06
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d850833d8k.htm   iXBRL 8-K 39245
2 EX-3.1 d850833dex31.htm EX-3.1 223698
3 EX-3.2 d850833dex32.htm EX-3.2 320530
7 GRAPHIC g850833g1212131117931.jpg GRAPHIC 2275
  Complete submission text file 0001193125-23-293433.txt   823528

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA biib-20231206.xsd EX-101.SCH 2861
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE biib-20231206_lab.xml EX-101.LAB 17982
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE biib-20231206_pre.xml EX-101.PRE 11266
9 EXTRACTED XBRL INSTANCE DOCUMENT d850833d8k_htm.xml XML 3411
Mailing Address 225 BINNEY STREET CAMBRIDGE MA 02142
Business Address 225 BINNEY STREET CAMBRIDGE MA 02142 7814642000
BIOGEN INC. (Filer) CIK: 0000875045 (see all company filings)

EIN.: 330112644 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19311 | Film No.: 231481686
SIC: 2836 Biological Products, (No Diagnostic Substances)